Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.58 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.58 |
| ▸ | TACR1 | P25103 | 3/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL25321406 | 0.99 | PRMT5 (0.57) | PRMT5WDR77TACR1RIPK1ALDH1A1 | |
| SCHEMBL25322511 | 0.76 | TACR1 (0.52) | PRMT5WDR77TACR1RIPK1 | |
| SCHEMBL24366004 | 0.75 | PRMT5 (0.77) | PRMT5WDR77 | |
| SCHEMBL24366003 | 0.75 | PRMT5 (0.77) | PRMT5WDR77 | |
| SCHEMBL25322517 | 0.71 | PRMT5 (0.58) | PRMT5WDR77RIPK1POLB | |
| SCHEMBL25918196 | 0.71 | PRMT5 (0.58) | PRMT5WDR77RIPK1POLB | |
| SCHEMBL25322520 | 0.71 | PRMT5 (0.58) | PRMT5WDR77RIPK1POLB | |
| SCHEMBL6828194 | 0.71 | POLB (0.53) | TACR1RIPK1DPP4DPP8DPP7 | |
| SCHEMBL27312840 | 0.71 | PRMT5 (0.44) | PRMT5WDR77RIPK1POLB | |
| SCHEMBL4613765 | 0.71 | RIPK1 (0.48) | RIPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | PRMT5 562/4885WDR77 1925/4885TACR1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.